$-0.02 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)

March 14, 2018 - By Dolores Ford

 $ 0.02 EPS Expected for AVEO Pharmaceuticals, Inc. (AVEO)
Investors sentiment increased to 1.32 in 2017 Q3. Its up 0.23, from 1.09 in 2017Q2. It improved, as 10 investors sold AVEO Pharmaceuticals, Inc. shares while 12 reduced holdings. 14 funds opened positions while 15 raised stakes. 59.90 million shares or 5.78% less from 63.58 million shares in 2017Q2 were reported.
Millennium Management Ltd holds 0.01% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) or 2.14 million shares. Eam Investors Ltd owns 785,338 shares. Morgan Stanley reported 61,072 shares. The Ontario – Canada-based Manufacturers Life Insur The has invested 0% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). Evercore Wealth has 168,414 shares for 0.02% of their portfolio. Venbio Select Advisor has invested 1.36% in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO). 683 Management Lc owns 2.52 million shares. State Bank Of America Corp De holds 6,000 shares or 0% of its portfolio. Vanguard Gru Incorporated Inc, a Pennsylvania-based fund reported 4.26M shares. Bridgeway Capital Mngmt has 346,464 shares. Gemmer Asset Mgmt Lc holds 0.01% or 1,939 shares in its portfolio. Deer Vi & Llc reported 675,242 shares. Pura Vida Investments Limited Company has 0.96% invested in AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) for 525,800 shares. Ra Capital Mgmt Limited Co stated it has 11.33M shares or 3.74% of all its holdings. Pnc Financial Serv owns 14,000 shares for 0% of their portfolio.

Analysts expect AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) to report $-0.02 EPS on March, 28.They anticipate $0.09 EPS change or 81.82 % from last quarter’s $-0.11 EPS. After having $-0.02 EPS previously, AVEO Pharmaceuticals, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 2.73% or $0.08 during the last trading session, reaching $2.85. About 1.30 million shares traded. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has declined 16.67% since March 15, 2017 and is downtrending. It has underperformed by 33.37% the S&P500.

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Ratings Coverage

Among 3 analysts covering AVEO Pharmaceuticals (NASDAQ:AVEO), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AVEO Pharmaceuticals had 13 analyst reports since March 30, 2016 according to SRatingsIntel. The firm earned “Buy” rating on Wednesday, August 9 by Piper Jaffray. The company was maintained on Tuesday, March 13 by FBR Capital. The rating was upgraded by Piper Jaffray on Monday, August 28 to “Buy”. The firm earned “Buy” rating on Monday, June 26 by FBR Capital. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) earned “Buy” rating by Piper Jaffray on Thursday, October 5. The stock of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) has “Buy” rating given on Monday, February 12 by FBR Capital. The stock has “Outperform” rating by FBR Capital on Wednesday, March 30. The rating was maintained by FBR Capital with “Buy” on Thursday, December 7. The firm earned “Overweight” rating on Thursday, May 19 by Piper Jaffray. The company was maintained on Tuesday, January 16 by FBR Capital.

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted therapies for cancer and related diseases. The company has market cap of $437.79 million. The company's pipeline of product candidates include Tivozanib, a vascular endothelial growth factor to optimize VEGF blockade; Ficlatuzumab, a hepatocyte growth factor (HGF) inhibitory antibody, which has completed Phase II trial that inhibits the activity of the HGF/c-Met pathway; and AV-203, an anti-ErbB3 specific monoclonal antibody that has completed a Phase I dose escalation study. It currently has negative earnings. The Company’s development programs also comprise AV-380, a humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; and the AV-353 platform for the potential treatment of pulmonary arterial hypertension.

Another recent and important AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) news was published by Zacks.com which published an article titled: “AVEO Pharmaceuticals’ (AVEO) Q4 Earnings: What’s in Store?” on March 06, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: